Metabolic Exercise Testing (RANNOU)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02362685|
Recruitment Status : Recruiting
First Posted : February 13, 2015
Last Update Posted : October 3, 2018
|Condition or disease||Intervention/treatment|
|Metabolic Myopathies Exercise Test Myalgia||Device: functional test Genetic: matching genotype with phenotype|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Exercise Testing in Metabolic Myopathies|
|Study Start Date :||September 2008|
|Estimated Primary Completion Date :||December 2022|
|Estimated Study Completion Date :||December 2022|
metabolic exercise testing
All the subjects referred to performed a metabolic exercise testing.
Device: functional test
subjects perform a metabolic exercise testing
Genetic: matching genotype with phenotype
- Whole-body dynamic exercise [ Time Frame: Participants will be followed for an expected average of 1 year to determine whether a muscle biopsy is performed ]The relation between Cardiopulmonary exercise test variables and the results of muscle biopsy or genetic analysis will be evaluated.
- Grip-test [ Time Frame: Participants will be followed for an expected average of 1 year to determine whether a muscle biopsy is performed ]The relation between Grip-test variables and the results of muscle biopsy or genetic analysis will be evaluated.
- Blood tests [ Time Frame: Participants will be followed for an expected average of 1 year to determine whether a muscle biopsy is performed ]The results of blood analysis from samples performed before, during, and after exercise will be compared to the results of muscle biopsy or genetic analysis.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02362685
|Contact: Fabrice Rannou, MD, PhD||33(0)email@example.com|
|Centre Hospitalier Régional Universitaire||Recruiting|
|Brest, France, 29609|
|Contact: Fabrice Rannou, MD, PhD 33(0)298347366 firstname.lastname@example.org|
|Principal Investigator:||Fabrice Rannou, MD, PhD||CHRU Brest|